Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from EQL Pharma AB ( (SE:EQL) ) is now available.
EQL Pharma AB, a Lund-headquartered generics specialist listed on the Spotlight Stock Market, collaborates with EU and Asian contract manufacturers to supply prescription and hospital pharmaceuticals across the Nordic region and select European markets. Its strategy centers on niche generic drugs, where competition is relatively limited and future launches are expected to expand its portfolio.
The company announced that CEO Axel Schörling has sold approximately SEK 1.2 million worth of shares to cover capital gains tax arising from the redemption of an option program in 2025. Schörling disposed of 24,066 shares, representing 5.8% of his holdings, and retains 389,892 shares, indicating he remains a significant shareholder despite the tax-driven sale.
More about EQL Pharma AB
EQL Pharma AB is a Sweden-based pharmaceutical company that develops and sells generic prescription drugs, focusing on niche generics with limited competition relative to reference products. The company has more than 47 approved niche generics in Nordic markets, a growing pipeline for 2026 and beyond, and operates mainly in the Nordic region and selected European markets from its base in Lund.
Average Trading Volume: 29,361
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.57B
For detailed information about EQL stock, go to TipRanks’ Stock Analysis page.